Classes
DEA Class; Rx
Common Brand Names; Cardizem, Cardizem CD, Cardizem LA, Cartia XT, Dilacor, Dilacor XR, Dilatrate, Diltazem, Diltazem CD, Dilt-CD, Diltia XT, Diltiaz, Diltiaz CD, Diltiaz SR, Diltiazem CD, Diltiazem SR, Dilzem, Taztia XT, Tiazac
- Antidysrhythmics, IV;
- Calcium Channel Blockers;
- Calcium Channel Blockers, Non-dihydropyridine
Description
Oral and IV, benzothiazepine calcium-channel blocker; primarily used for angina, HTN, PST, and ventricular rate control in AFIB; slows AV conduction; vasodilatory properties; less negative inotropic effects than verapamil or nifedipine.
Indications
Indicated for the treatment of hypertension.
Contraindications
Hypersensitivity
Wolff-Parkinson-White syndrome, Lown-Ganong-Levine syndrome, symptomatic severe hypotension (systolic BP <90 mm Hg), sick sinus syndrome (if no pacemaker), 2°/3° (if no pacemaker); heart block
PO: Acute MI and pulmonary congestion
IV: Use in newborns (because of benzyl alcohol), concomitant beta-blocker therapy, cardiogenic shock, ventricular tachycardia (must determine whether origin is supraventricular or ventricular)
Adverse Effects
- Edema (2-15%)
- Headache (5-12%)
- Dizziness (3-10%)
- AV block (2-8%)
- Peripheral edema (2-8%)
- Bradyarrhythmia (2-6%)
- Headache (1-5%)
- Hypotension (2-4%)
- Nausea (3%)
- Vomiting (2%)
- Vasodilation (2-3%)
- Extrasystoles (2%)
- Flushing (1-2%)
- Drug-induced gingival hyperplasia (<2%)
- Myalgia (2%)
- Diarrhea (1-2%)
- Constipation (2-4%)
- Bronchitis (1-4%)
- Sinus congestion (1-2%)
- Dyspnea (1-6%)
- Congestion (1-2%)
- Increased Alkaline phosphatase as well as ALT and AST
- CHF
- Thrombocytopenia
- Toxic epidermal necrolysis
- Hemolytic anemia
- Photosensitivity
- Extrapyramidal symptoms
- Syncope
Warnings
May cause abnormally slow heart rates or second- or third-degree AV block’ patients with sick sinus syndrome are at increased risk of bradycardia (risk increases with agents known to slow cardiac conduction
Stevens-Johnson syndrome, toxic epidermal necrolusis, erythema multiforme and/or exfoliative dermatitis reported
Significant elevations in liver enzymes such as alkaline phosphatase, LDH, AST (SGOT), ALT (SGPT) and signs of acute hepatic injury reported; reversible upon discontinuation of drug therapy
Mild elevations of transaminases with and without concomitant elevation in alkaline phosphatase and bilirubin observed; elevations were usually resolved even with continued diltiazem treatment
Symptomatic hypotension with or without syncope reported
Peripheral edema occurs within 2-3 weeks of starting therapy
Use with caution in hypertrophic obstructive cariomyopathy, hepatic/renal impairment, left ventricular dysfunction
Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction; sinus bradycardia resulting in hospitalization reported with concurrent use of clonidine and other agents that slow cardiac conduction
May increase the risk of adverse cardiac events in patients with heart failure due to negative inotropic effects (risk directly related to the severity of baseline HF)
Pregnancy and Lactation
Pregnancy category: C
Lactation: Drug enters breast milk; because of risk for serious adverse reactions in nursing infants from diltiazem, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother
Maximum Dosage
360 mg/day PO for diltiazem tablets and twice-daily extended-release capsules (e.g., Cardizem, Cardizem SR); 540 mg/day PO for hypertension for once-daily extended-release formulations (e.g., Dilacor-XR capsules, Tiazac capsules, Cardizem CD, Cardizem LA tablets).
360 mg/day PO for diltiazem tablets and twice-daily extended-release capsules (e.g., Cardizem, Cardizem SR); 540 mg/day PO for hypertension for once-daily extended-release formulations (e.g., Dilacor-XR capsules, Tiazac capsules, Cardizem CD, Cardizem LA tablets).
Safety and efficacy have not been established; doses of 6 mg/kg (up to 360 mg) per day PO have been used off-label for hypertension.
Safety and efficacy have not been established; doses of 6 mg/kg (up to 360 mg) per day PO have been used off-label for hypertension.
How supplied
Diltiazem hydrochloride
capsule/tablet, extended release
- 120mg
- 180mg
- 240mg
- 300mg
- 360mg
- 420mg
injectable solution
- 5mg/mL
powder for injection
- 100mg
tablet
- 30mg
- 60mg
- 90mg
- 120mg